Topical ivermectin cream, 1% (Soolantra, Galderma) represents an advance in treatment for rosacea, offering superior efficacy and tolerability compared with previously available therapies, says Jeffrey S. Fromowitz, M.D., who spoke at the Orlando Dermatology Aesthetic & Clinical Conference.
Because of its benefits, ivermectin is also changing the treatment paradigm for rosacea, shifting the goal to targeting “clear” status for patients rather than settling for “near clear,” according to Dr. Fromowitz, medical director of Dermatology of Boca, Boca Raton, Fla.
“With ivermectin it is now possible to drive more patients with rosacea towards an outcome of ‘clear’ versus ‘near clear’. That is a clinically relevant distinction considering available data on the psychosocial burdens of rosacea and showing the benefit of achieving disease clearance for a longer treatment-free interval,” he says.
As an inflammatory condition involving facial skin, rosacea can have significant quality of life consequences for individuals. Studies of patients with rosacea highlight how the disease affects their self-esteem and creates feelings of helplessness, depression, embarrassment, anger, and it raises social anxiety levels.
In addition, research shows that significant proportions of patients with rosacea rate their disease as having a moderate or greater negative impact on their life and report spending several hours a day dealing with their disease. Considering findings from studies asking for input on the qualities of people with rosacea, the emotional toll of rosacea reported by patients is not unwarranted.
Dr. Fromowitz has received speaking and consulting fees from Galderma.